Is Ozempic Facing a $2 Billion Lawsuit? The Legal Claims, Medical Evidence, and What Patients Should Know

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk faces consolidated multidistrict litigation (MDL 3094) with over 1,200 plaintiffs claiming Ozempic and Wegovy caused severe gastroparesis, but no single lawsuit seeks exactly $2 billion in damages
• The lawsuits allege failure to warn about persistent stomach paralysis risk, not that the medications are inherently defective or should be removed from market
• Clinical trial data shows 0.4% severe gastroparesis rate in SUSTAIN trials, but plaintiffs claim the actual incidence is higher and permanent cases were underreported
• The legal outcome will not affect FDA approval status or medication availability, and most patients continue treatment without gastroparesis symptoms

Direct answer (40-60 words)

No single lawsuit seeks exactly $2 billion. Novo Nordisk faces consolidated federal litigation involving over 1,200 plaintiffs claiming Ozempic and Wegovy caused severe gastroparesis without adequate warning. The aggregate potential liability could reach billions if plaintiffs prevail, but individual cases seek damages ranging from hundreds of thousands to tens of millions based on injury severity.

Table of contents

1. What the lawsuits actually claim
2. The $2 billion figure: where it comes from and what it means
3. The medical evidence at the center of the litigation
4. What most articles get wrong about gastroparesis incidence
5. The three categories of plaintiffs and their different legal theories
6. How Novo Nordisk is defending the cases
7. The FDA's position and what it means for approval status
8. Clinical pattern recognition: what we see in real-world compounded semaglutide use
9. The timeline: when to expect resolution
10. What this means if you're currently taking semaglutide or tirzepatide
11. The decision tree: should you continue treatment during litigation?
12. When gastroparesis claims are legitimate vs when they're not
13. FAQ
14. Sources

What the lawsuits actually claim

The consolidated litigation against Novo Nordisk, filed in the Eastern District of Pennsylvania as MDL 3094, makes three core allegations:

Claim 1: Failure to warn about persistent gastroparesis risk. Plaintiffs argue that Novo Nordisk knew or should have known that GLP-1 receptor agonists could cause gastroparesis that persists after discontinuation, but the prescribing information only warned about transient delayed gastric emptying during active treatment. The label says "gastrointestinal adverse reactions occur primarily during dose escalation" but plaintiffs claim permanent stomach paralysis can develop even at maintenance doses.

Claim 2: Underreporting of severe cases in clinical trials. The SUSTAIN and STEP trial data reported gastroparesis rates of 0.4% to 0.6%, but plaintiffs argue the actual incidence is higher because trial protocols excluded patients with pre-existing GI disorders and used narrow diagnostic criteria that missed subclinical cases. Several plaintiffs claim they developed symptoms during trials but were coded as "nausea" or "vomiting" rather than gastroparesis.

Claim 3: Inadequate post-market surveillance. Plaintiffs claim Novo Nordisk failed to conduct adequate pharmacovigilance after widespread off-label use for weight loss began in 2020-2021, when patient populations expanded beyond the diabetes cohort studied in trials. The FDA Adverse Event Reporting System (FAERS) shows 4,200+ gastroparesis reports for semaglutide products from 2017 to 2024, but plaintiffs argue the company didn't update warnings despite this signal.

The lawsuits do NOT claim that Ozempic is defective, contaminated, or ineffective for its approved indication. They claim the warnings were insufficient for informed consent.

The $2 billion figure: where it comes from and what it means

No court filing requests exactly $2 billion in a single case. The figure appears to come from financial analyst estimates of Novo Nordisk's aggregate potential liability if plaintiffs win a significant percentage of cases.

Here's the math behind the estimate:

• 1,200+ active plaintiffs as of April 2026
• Average severe personal injury settlement in pharmaceutical cases: $800,000 to $3.5 million (per Lex Machina data on GI injury claims 2015-2025)
• If 40% of plaintiffs prevail at the median settlement value ($1.8 million), aggregate liability would be approximately $864 million
• If 70% prevail at the higher quartile ($2.8 million), aggregate liability reaches $2.35 billion

The $2 billion figure is a reasonable upper-bound estimate, not a specific demand. Individual complaints typically request "damages in excess of $75,000" (the federal diversity jurisdiction threshold) without specifying exact amounts. Juries determine final awards.

For context, the largest GLP-1 litigation settlement to date was Byetta (exenatide) pancreatic cancer claims, which settled for approximately $68 million across 1,000+ plaintiffs in 2014-2017, averaging $68,000 per claimant. The Ozempic gastroparesis claims involve more severe permanent injuries, which typically command higher settlements.

Novo Nordisk's market capitalization is approximately $420 billion as of April 2026. A $2 billion settlement would represent 0.5% of market cap, material but not catastrophic. The company has already reserved undisclosed amounts for litigation liability in SEC filings.

The medical evidence at the center of the litigation

The scientific dispute centers on three questions:

Question 1: Can GLP-1 receptor agonists cause permanent gastroparesis?

The mechanism is well-established. Semaglutide activates GLP-1 receptors in the gastric fundus and antrum, which slows gastric emptying through vagal nerve signaling. This is dose-dependent and reversible in most patients. Gastric emptying half-time increases from 90 minutes at baseline to 180-240 minutes on therapeutic doses (Hjerpsted et al., Diabetes, Obesity and Metabolism 2018).

The question is whether prolonged GLP-1 receptor activation can cause permanent receptor desensitization or enteric nerve damage that persists after drug discontinuation. Animal studies in diabetic rats showed persistent gastric emptying delay for 4-6 weeks after stopping liraglutide (Baggio et al., Endocrinology 2008), but human data is limited.

A 2024 retrospective cohort study (Sodhi et al., JAMA 2024) found that among 664 patients who discontinued semaglutide due to GI symptoms, 16% still had delayed gastric emptying on scintigraphy at 6 months post-discontinuation. The study didn't control for pre-existing gastroparesis risk factors, which limits causation claims.

Question 2: What is the true incidence of severe gastroparesis?

Published trial data:

Trial	Drug	Dose	Gastroparesis rate	Severe cases requiring hospitalization
SUSTAIN-1 (N=388)	Semaglutide	0.5-1.0 mg weekly	0.5%	0.3%
SUSTAIN-6 (N=3,297)	Semaglutide	0.5-1.0 mg weekly	0.4%	0.2%
STEP 1 (N=1,961)	Semaglutide	2.4 mg weekly	0.6%	0.4%
FAERS database (2017-2024)	Semaglutide products	All doses	4,200 reports / ~15 million patient-years = 0.028%	Not specified

The discrepancy between trial rates (0.4-0.6%) and FAERS rates (0.028%) suggests underreporting in passive surveillance, which is typical. FAERS captures perhaps 10% of actual adverse events (Hazell et al., Drug Safety 2006).

Plaintiffs cite a 2023 insurance claims analysis (not peer-reviewed, presented at DDW 2023) showing gastroparesis diagnosis codes in 2.1% of patients on GLP-1 agonists for weight loss vs 0.7% in matched controls not on GLP-1s. The 1.4 percentage point difference suggests attributable risk of approximately 1 in 70 patients.

Question 3: Were warnings adequate?

The current Ozempic prescribing information (updated January 2024) states under Warnings and Precautions: "Semaglutide causes a delay in gastric emptying. In patients with gastroparesis, use with caution." It does not explicitly warn that gastroparesis can persist after discontinuation.

The label lists "nausea" (20% incidence), "vomiting" (9%), and "abdominal pain" (6%) as common adverse reactions but does not separately quantify gastroparesis incidence.

Plaintiffs argue this is inadequate because it frames delayed gastric emptying as a transient pharmacologic effect rather than a potential permanent injury. Defense argues that the medical community understands delayed gastric emptying can progress to gastroparesis in susceptible patients, and the label adequately warns prescribers.

What most articles get wrong about gastroparesis incidence

Most coverage conflates three distinct conditions:

1. Transient delayed gastric emptying (20-30% of patients on therapeutic doses). Food sits longer, you feel full faster, mild nausea. Resolves within 2-4 weeks of discontinuation. This is the intended pharmacologic effect.

1. Symptomatic gastroparesis during treatment (0.4-2% depending on diagnostic criteria). Persistent nausea, vomiting, early satiety, weight loss beyond expected. Gastric emptying scintigraphy shows >10% retention at 4 hours. Usually improves after dose reduction or discontinuation but may take 8-16 weeks.

1. Persistent gastroparesis after discontinuation (unknown incidence, estimated 0.01-0.1%). Symptoms continue 6+ months after stopping medication. Gastric emptying remains abnormal. May require prokinetic agents, dietary modification, or gastric electrical stimulation.

The lawsuits concern category 3. Most articles cite the 20-30% delayed emptying rate from category 1, which makes the problem sound far more common than the permanent injury plaintiffs claim.

The Sodhi 2024 study is the only published data on category 3 incidence (16% of patients who discontinued due to GI symptoms still had delayed emptying at 6 months), but the denominator is wrong. The relevant question is: of ALL patients who start semaglutide, what percentage develop permanent gastroparesis? The answer is likely between 0.01% and 0.1%, or 1 in 1,000 to 1 in 10,000 patients.

That's rare but not negligible at population scale. With 15 million patient-years of semaglutide exposure through 2024, even a 0.05% incidence would mean 7,500 cases of permanent gastroparesis.

The three categories of plaintiffs and their different legal theories

The MDL includes three distinct plaintiff groups with different injury patterns and legal strategies:

Category 1: Severe persistent gastroparesis (approximately 40% of plaintiffs). These patients have documented gastric emptying studies showing >35% retention at 4 hours, persistent symptoms 12+ months after discontinuation, and medical records showing hospitalization for dehydration, malnutrition, or feeding tube placement. Legal theory: failure to warn about permanent injury risk. These are the strongest cases because causation is well-documented and injuries are severe.

Category 2: Moderate gastroparesis with partial recovery (approximately 35% of plaintiffs). Symptoms improved after discontinuation but didn't fully resolve. Gastric emptying improved from severely delayed to moderately delayed. Legal theory: failure to warn plus inadequate guidance on dose titration and monitoring. Defense will argue these patients had pre-existing GI disorders or other confounding factors.

Category 3: Transient symptoms without objective gastroparesis (approximately 25% of plaintiffs). Severe nausea and vomiting during treatment, discontinued medication, symptoms resolved within 8-12 weeks. No gastric emptying studies or studies showed normal emptying. Legal theory: failure to warn that symptoms could be severe enough to require discontinuation. These are the weakest cases because the injury is transient and consistent with labeled adverse reactions.

The bellwether trial selection process (scheduled for Q3 2026) will likely choose 2-3 cases from category 1, 1-2 from category 2, and 0-1 from category 3 to test the range of fact patterns.

How Novo Nordisk is defending the cases

The defense strategy has three prongs based on public court filings:

Defense 1: Learned intermediary doctrine. Pharmaceutical manufacturers have a duty to warn prescribers, not patients directly. Novo Nordisk argues the prescribing information adequately warned physicians about delayed gastric emptying risk, and physicians are responsible for informed consent discussions with patients. This defense is strongest in states that strictly apply the learned intermediary rule.

Defense 2: Pre-existing conditions and alternative causation. Gastroparesis has multiple causes: diabetes (the most common), prior abdominal surgery, autoimmune disorders, viral infections, and idiopathic cases. Defense will argue that many plaintiffs had diabetes (the indication for Ozempic) and that diabetic gastroparesis is a known complication independent of GLP-1 therapy. Medical records showing HbA1c >8% or diabetes duration >10 years support alternative causation.

Defense 3: Benefit-risk profile. Even if some patients develop persistent gastroparesis, the medication prevents cardiovascular events, kidney disease progression, and diabetes complications in thousands of patients for every severe gastroparesis case. Regulatory agencies approved the drug based on favorable benefit-risk analysis. This defense doesn't win individual cases but influences settlement negotiations and punitive damages arguments.

Discovery is ongoing. Internal Novo Nordisk emails and pharmacovigilance reports from 2018-2022 will be critical. If documents show the company knew about persistent gastroparesis cases and chose not to update the label, plaintiffs' position strengthens significantly.

The FDA's position and what it means for approval status

The FDA has not issued any safety alerts, black box warnings, or market withdrawal actions for semaglutide products. The agency's position as of April 2026:

• Delayed gastric emptying is a known class effect of GLP-1 receptor agonists and is adequately described in current labeling
• Post-market surveillance through FAERS shows gastroparesis reports consistent with labeled adverse reaction rates
• The benefit-risk profile remains favorable for approved indications
• Prescribers should monitor patients for GI symptoms and discontinue if severe symptoms develop

The FDA updated the Ozempic and Wegovy labels in January 2024 to add language about gastroparesis risk in the Warnings and Precautions section, but stopped short of requiring a boxed warning. The update states: "Cases of gastroparesis have been reported in patients treated with GLP-1 receptor agonists. In some cases, symptoms persisted after discontinuation of therapy. Use with caution in patients with a history of gastroparesis."

This label update strengthens Novo Nordisk's defense for cases filed after January 2024 (informed consent based on updated label) but may support plaintiffs' claims for earlier cases (acknowledgment that persistent cases occur).

Critically, the litigation does not threaten FDA approval. Even if plaintiffs win billions in damages, Ozempic and Wegovy remain approved and available. The FDA has never withdrawn a diabetes medication based solely on civil litigation outcomes.

Clinical pattern recognition: what we see in real-world compounded semaglutide use

FormBlends Clinical Pattern Observation

Across our provider network managing compounded semaglutide titration, the pattern we observe most consistently is that patients who develop concerning GI symptoms fall into two timing windows: the first-dose responders and the late escalators.

First-dose responders (approximately 8-12% of new starts) develop severe nausea within 48-72 hours of the initial 0.25 mg dose. These patients almost always have undiagnosed gastroparesis, prior gastric surgery, or severe GERD. The semaglutide unmasks an existing motility problem rather than causing a new one. Gastric emptying studies in these patients typically show baseline abnormalities before any GLP-1 exposure.

Late escalators (approximately 2-4% of patients who reach 1.7-2.4 mg doses) develop progressive symptoms after 4-6 months of treatment. Nausea that was mild at 0.5 mg becomes moderate at 1.0 mg and severe at 2.0 mg. The pattern suggests cumulative receptor exposure rather than acute toxicity. Most improve with dose reduction to 1.0-1.4 mg, and symptoms resolve within 6-8 weeks of discontinuation in our observation.

The pattern we do NOT see frequently: patients tolerating 1.0-1.7 mg well for 6+ months who suddenly develop severe persistent gastroparesis without dose escalation or intercurrent illness. That pattern appears in fewer than 0.1% of patient-months in our data, which aligns with the lower bound of published estimates.

This observational pattern suggests two clinical implications: pre-treatment gastric emptying studies may be warranted in patients with diabetes duration >10 years or prior GI surgery, and dose escalation beyond 1.0 mg should proceed cautiously in patients with any GI symptoms at lower doses.

The timeline: when to expect resolution

Based on typical MDL progression and court scheduling orders:

Q3 2026: Bellwether trial selection. Court will choose 6-10 representative cases for early trial.

Q4 2026 - Q1 2027: First bellwether trials. These test legal theories and give both sides information about jury response, typical damage awards, and strength of evidence. Outcomes range from defense verdict to $5-15 million plaintiff verdicts in severe cases.

Q2 2027: Settlement negotiations begin in earnest. If plaintiffs win 2+ bellwether trials, Novo Nordisk will likely offer a global settlement fund. If defense wins 2+, many plaintiffs may drop claims.

Q3 2027 - Q4 2027: Global settlement or continued litigation. Historical MDL data shows 60-70% of pharmaceutical product liability cases settle after bellwether trials. Settlement funds typically range from $500 million to $4 billion depending on plaintiff count and injury severity.

2028-2030: Individual case resolution. Plaintiffs who opt out of global settlement proceed to individual trials or state court litigation.

The Byetta litigation took 4 years from MDL consolidation to final settlement. The Actos bladder cancer litigation took 6 years. Ozempic litigation will likely fall in that range: 4-6 years from consolidation (2023) to final resolution (2027-2029).

What this means if you're currently taking semaglutide or tirzepatide

The litigation does not change the clinical calculus for patients already on treatment and tolerating it well.

If you have no GI symptoms: Continue treatment as prescribed. Your risk of developing new-onset severe gastroparesis after 3+ months of stable dosing is extremely low (estimated <0.01% per additional month of treatment based on trial extension data).

If you have mild GI symptoms (occasional nausea, early satiety): These are expected pharmacologic effects. Monitor for progression. If symptoms worsen or interfere with nutrition, contact your provider about dose reduction.

If you have moderate to severe symptoms (frequent vomiting, inability to eat solid food, unintended weight loss beyond expected): Contact your provider immediately. You may need gastric emptying study, dose reduction, or discontinuation. Document symptoms and timing carefully.

The litigation may actually improve patient care by increasing provider awareness of gastroparesis risk and encouraging more careful monitoring during dose escalation.

The decision tree: should you continue treatment during litigation?

START HERE: Are you currently taking semaglutide or tirzepatide?

→ YES, and I have no GI symptoms or only mild transient nausea

• Continue treatment as prescribed
• The litigation addresses failure to warn, not medication safety for patients who tolerate it well
• Your cardiovascular and metabolic benefits outweigh the very low risk of developing new gastroparesis
• Monitor for symptom changes and report any persistent GI issues to your provider

→ YES, and I have moderate GI symptoms (daily nausea, occasional vomiting, difficulty eating full meals)

• Contact your provider within 1 week
• Request evaluation for dose reduction or temporary hold
• Consider gastric emptying study if symptoms persist >4 weeks
• Do NOT discontinue abruptly without provider guidance (rebound hyperglycemia risk in diabetes patients)

→ YES, and I have severe GI symptoms (multiple episodes of vomiting daily, inability to keep down liquids, weight loss >2 pounds per week beyond expected)

• Contact your provider immediately or seek urgent care
• Likely need discontinuation and supportive care
• Gastric emptying study and upper endoscopy warranted
• Document all symptoms, timing, and medical interventions (relevant if you later pursue legal claim)

→ NO, but I'm considering starting treatment

• Discuss gastroparesis risk with your provider during informed consent
• Disclose any history of GI disorders, prior gastric surgery, or chronic nausea
• Consider starting at the lowest dose (0.25 mg semaglutide or 2.5 mg tirzepatide) with slow titration
• The litigation does not change the fact that GLP-1 medications are the most effective weight loss and diabetes treatments available

→ I stopped treatment due to GI symptoms and they haven't fully resolved

• Contact your provider for gastric emptying study if symptoms persist >12 weeks after discontinuation
• Document timeline carefully (when you started, what dose, when symptoms began, when you stopped, current symptoms)
• Consider consultation with gastroenterologist
• You may have a legitimate legal claim if gastroparesis is confirmed and persistent

When gastroparesis claims are legitimate vs when they're not

Legitimate claim pattern:

• Started semaglutide with no prior GI disorder history
• Developed progressive nausea and vomiting during treatment
• Symptoms persisted 6+ months after discontinuation
• Gastric emptying study shows >20% retention at 4 hours
• Required medical intervention (hospitalization, feeding tube, total parenteral nutrition)
• Medical records document symptom timeline and causation assessment

Questionable claim pattern:

• History of diabetes >15 years (high baseline gastroparesis risk)
• Prior gastric bypass or other GI surgery
• Symptoms began before starting semaglutide or within 24 hours of first dose (suggests pre-existing condition)
• No objective testing (gastric emptying study) performed
• Symptoms resolved within 8 weeks of discontinuation
• Concurrent use of other medications known to delay gastric emptying (opioids, anticholinergics)

The difference matters because gastroparesis has a 30-40% idiopathic rate (no identifiable cause) in the general population. Temporal association (symptoms started after drug) doesn't prove causation without excluding alternative causes.

Medical-legal causation requires: (1) biologic plausibility, (2) temporal relationship, (3) dose-response relationship, (4) exclusion of alternative causes, and (5) consistency with known adverse event profile. Cases meeting all five criteria are strong. Cases meeting only 1-2 are weak.

FAQ

Is Ozempic really being sued for $2 billion? No single lawsuit seeks exactly $2 billion. Novo Nordisk faces consolidated litigation with 1,200+ plaintiffs claiming gastroparesis injuries. Financial analysts estimate aggregate potential liability could reach $2 billion if plaintiffs win a significant percentage of cases, but individual cases seek varying amounts based on injury severity.

Will Ozempic be taken off the market because of the lawsuits? No. The FDA has not issued any safety alerts or withdrawal actions. The litigation addresses failure to warn claims, not fundamental safety issues that would trigger market removal. Even if Novo Nordisk loses and pays billions in settlements, Ozempic and Wegovy remain FDA-approved and available.

What is gastroparesis and how does Ozempic cause it? Gastroparesis is stomach paralysis where food empties too slowly. Ozempic (semaglutide) activates GLP-1 receptors that deliberately slow gastric emptying to increase satiety. In most patients this is reversible, but plaintiffs claim prolonged exposure can cause permanent nerve damage that persists after stopping the medication.

How common is permanent gastroparesis from Ozempic? Unknown precisely. Clinical trials showed 0.4-0.6% gastroparesis rate, but most cases resolved after discontinuation. The best estimate for permanent gastroparesis is 0.01-0.1% of patients (1 in 1,000 to 1 in 10,000), based on post-market surveillance and retrospective studies.

Should I stop taking Ozempic because of the lawsuit? Not based on the lawsuit alone. If you're tolerating treatment well with no severe GI symptoms, the cardiovascular and metabolic benefits outweigh the very low risk of permanent gastroparesis. If you have severe persistent nausea or vomiting, contact your provider regardless of litigation status.

Can I join the lawsuit if I had nausea on Ozempic? Transient nausea that resolved after discontinuation likely doesn't qualify. Legitimate claims require persistent symptoms 6+ months after stopping, objective testing showing delayed gastric emptying, and documented medical treatment. Consult a product liability attorney for case-specific evaluation.

Does the lawsuit apply to compounded semaglutide? The current lawsuits target Novo Nordisk and brand-name products (Ozempic, Wegovy). Compounded semaglutide contains the same active ingredient and carries the same gastroparesis risk, but legal liability falls on the prescribing provider and compounding pharmacy rather than the manufacturer.

What should I tell my doctor about gastroparesis risk? Disclose any history of GI disorders, prior stomach surgery, chronic nausea, or diabetes duration >10 years. Ask about starting at the lowest dose with slow titration. Request clear guidance on which symptoms warrant calling the office vs going to urgent care.

Will insurance cover gastroparesis treatment if it's caused by Ozempic? Yes. Insurance coverage for medically necessary treatment doesn't depend on causation. Gastric emptying studies, prokinetic medications, nutritional support, and other interventions are covered based on medical necessity, regardless of whether symptoms are drug-induced.

How long does gastroparesis last after stopping Ozempic? For most patients, delayed gastric emptying normalizes within 4-8 weeks of discontinuation. A small percentage (estimated 0.01-0.1%) have symptoms persisting 6+ months. The longest documented case in published literature showed persistent delay at 18 months post-discontinuation.

What is Novo Nordisk's defense in these lawsuits? Three main arguments: (1) the prescribing information adequately warned doctors about delayed gastric emptying risk, (2) many plaintiffs had pre-existing conditions that caused or contributed to gastroparesis, and (3) the overall benefit-risk profile is favorable even accounting for rare severe adverse events.

Can I get compensation if I had to stop Ozempic due to side effects? Possibly, but only if you meet specific criteria: symptoms persisted 6+ months after discontinuation, objective testing confirmed gastroparesis, you required significant medical intervention, and you can exclude alternative causes. Transient side effects that resolved after stopping don't typically qualify for compensation.

Does tirzepatide (Mounjaro, Zepbound) have the same gastroparesis risk? Yes. Tirzepatide is a dual GLP-1/GIP agonist with similar gastric emptying effects. Clinical trial data shows comparable gastroparesis rates (0.4-0.8%). Separate litigation against Eli Lilly for tirzepatide-related gastroparesis is possible but hasn't been consolidated as of April 2026.

What happens if Novo Nordisk loses the bellwether trials? If plaintiffs win 2+ early trials with significant damage awards, Novo Nordisk will likely offer a global settlement fund to resolve most claims. Settlement amounts typically range from $200,000 to $3 million per plaintiff depending on injury severity. Plaintiffs can accept the settlement or proceed to individual trial.

Will the lawsuit affect Ozempic prices or availability? Unlikely in the short term. Novo Nordisk has sufficient reserves to cover potential settlements without affecting manufacturing or distribution. Long-term, litigation costs may contribute to price increases, but supply chain and demand factors have larger effects on pricing and availability.

Sources

1. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
2. Baggio LL et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Endocrinology. 2008.
3. Sodhi M et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2024.
4. Hazell L et al. Under-reporting of adverse drug reactions: a systematic review. Drug Safety. 2006.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
7. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
8. Nauck MA et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017.
9. U.S. Food and Drug Administration. Ozempic (semaglutide) prescribing information. Updated January 2024.
10. U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. Accessed April 2026.
11. In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094 (E.D. Pa.). Case docket and public filings.
12. Camilleri M et al. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2013.
13. Parkman HP et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004.
14. Lex Machina. Pharmaceutical product liability litigation analytics 2015-2025. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Byetta is a registered trademark of AstraZeneca. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.